IgGenix Announces Jessica Grossman, M.D., as Chief Executive Officer

SOUTH SAN FRANCISCO, Calif. – June 24, 2021 – IgGenix, Inc., a biotechnology company taking a revolutionary approach to directly address allergic disease, announced that Jessica Grossman, M.D., has joined IgGenix as chief executive officer (CEO). Dr. Grossman has over two decades of experience in the medical, pharmaceutical and biotechnology fields.

Dr. Grossman has dedicated her career to advancing science through leading businesses and non-for-profits through various phases of growth. Prior to joining IgGenix, Dr. Grossman served as CEO of Medicines360, a commercial stage pharmaceutical organization working to advance clinical research in women’s health and to ensure that all women have access to the most effective forms of birth control. Prior to joining Medicines360, she served as president and CEO of Sense4Baby, Inc. and she currently serves on the board of directors of Daré Bioscience, Inc. Dr. Grossman holds numerous patents and has published several peer reviewed articles. Dr. Grossman holds a Bachelor of Arts in Biology and English from Brandeis University and a Doctor of Medicine from Thomas Jefferson University.

“IgGenix has the opportunity to change the face of allergic disease by re-engineering key monoclonal antibodies involved in the allergic cascade,” Dr. Grossman said. “Our vision is a future where people live without the constant fear of a life-threatening allergic reaction. Allergies have a potentially deadly impact on the lives of millions of people, and IgGenix is uniquely positioned to deliver a first-in-class therapy that addresses this unmet need.”

In recent months, IgGenix has made significant discoveries using single cell RNA sequence to identify allergen-specific human IgE antibodies to over a dozen of food and non-food allergens. Dr. Grossman is spearheading business development and expanding research to rapidly identify promising treatment candidates.

Food Allergies: An Urgent Need for Effective Options

Food allergies impact approximately 32 million Americans, 200 million people globally, and their incidence is on the rise. Every three minutes, someone visits an emergency room for food-induced anaphylaxis. The current standard of care is strict allergen avoidance, which has many negative effects, including reduced quality of life, social isolation, and potential for life-threatening reactions.

About IgGenix

IgGenix is a privately held biotechnology company taking a revolutionary approach to directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. Founded based on research by professors Stephen Quake and Kari Nadeau of Stanford University, IgGenix isolates allergen-specific IgE antibodies and transforms them into IgG antibodies that alleviate and possibly prevent the allergic cascade. This novel approach may prevent life-threatening allergic reactions, saving lives and reducing the constant fear that affects people living with severe allergies.


Investor Inquiries
Jessica Grossman

Media Inquiries
Janine Bogris